Recent Findings from Zucker School of Medicine at Hofstra Highlight Research in Venous Thromboembolism (Inadequate Anti-Factor Xa Levels With Daily 40-mg Enoxaparin After Cardiac Surgery).

A recent report from the Zucker School of Medicine at Hofstra highlights research on venous thromboembolism (VTE) in cardiac surgery patients. The study aimed to determine if the standard dose of enoxaparin, a blood thinner, achieved adequate anti-factor Xa (aFXa) levels for VTE prevention in patients after open heart surgery. The results showed that the daily administration of 40 mg of enoxaparin led to subprophylactic aFXa levels for most patients. Further studies are needed to assess the clinical relevance of these findings. [Extracted from the article]